Search results
‘A study to give us hope’: Lifestyle changes improve Alzheimer’s symptoms for some
CNN via Yahoo News· 6 days agoFollowing a vegan diet, reducing stress, exercising and sharing feelings with others helped people...
'Exciting' new Parkinson's treatment may cure root cause
Newsweek· 4 days agoAn "exciting" new Parkinson's disease drug promises to not only treat but to cure the condition at...
The regionality and seasonality of tornado trends in the United States - npj Climate and Atmospheric...
Nature· 3 days ago1, and defined a tornado day as any calendar day with at least one (E)F-1+ tornado, and a tornado outbreak day as any day with more than 30 (E)F-1+ tornadoes1. Over the 63-year period of our ...
Lilly’s Phase II results in Alzheimer’s disease have most experts saying donanemab is done
Clinical Trials Arena via Yahoo Finance· 7 days agoEli Lilly’s donanemab for early symptomatic Alzheimer’s disease (AD) has most experts dubious of the...
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
Motley Fool via Yahoo Finance· 7 days agoIn this study, which was conducted in China, patients receiving the ivonescimab/chemo combo achieved...
FDA approves new drug to treat autoimmune liver disease: ‘Giant step forward’
Fox News· 3 days agoA new drug to control liver disease has gotten the green light. The U.S. Food and Drug...
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study - Intra-Cellular...
Benzinga· 5 days agoLumateperone 42 mg, given once daily as adjunctive therapy to antidepressants, met the primary...
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies What's Going On...
Benzinga· 6 days agoMonday, Takeda Pharmaceutical Co Ltd TAK announced topline data from its SKYLINE and SKYWAY Phase 3...
Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy
Investor's Business Daily· 2 days agoSarepta stock rocketed Friday after hitting a "grand slam" approval that expands the market for its...
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Zacks via Yahoo Finance· 4 days agoIntra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating...